Colchicine: Old and New - 24/04/15
, Svetlana Krasnokutsky, MD, MSCI a, bAbstract |
Although colchicine has been a focus of research, debate, and controversy for thousands of years, the US Food and Drug Administration just approved it in 2009. Over the past decade, advances in the knowledge of colchicine pharmacology, drug safety, and mechanisms of action have led to changes in colchicine dosing and to potential new uses for this very old drug. In this review, we discuss the pharmacologic properties of colchicine and summarize what is currently known about its mechanisms of action. We then discuss and update the use of colchicine in a variety of illnesses, including rheumatic and, most recently, cardiovascular diseases.
Le texte complet de cet article est disponible en PDF.Keywords : Cardiovascular disease, Colchicine, Gout, Inflammation
Plan
| Funding: None. |
|
| Conflict of Interest: AS: None. SK: None. MHP is the recipient of an investigator-initiated grant and also serves as a study site investigator for a trial supported by Takeda, Inc.; is the recipient of an investigator-initiated grant from Savient, Inc.; is the recipient of an investigator-initiated grant and has served as a consultant for Crealta, Inc.; and has served as a consultant for Astra-Zeneca, Inc. BS is the recipient of an investigator-initiated grant (drug and placebo only) from Takeda, Inc. |
|
| Authorship: All authors participated in all aspects of this manuscript, including conception, research, writing, and editing. |
Vol 128 - N° 5
P. 461-470 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
